Agios outlines $45M-$50M 2026 PK deficiency revenue as November 1 sickle cell PDUFA approaches

FDA DecisionPositive

AI Analysis

Summary

Agios Pharmaceuticals outlines 2026 revenue expectations of $45M-$50M for its PK deficiency treatment ahead of a November 1 PDUFA decision for a sickle cell indication.

Financial Highlights

Revenue

$45M-$50M

Guidance

2026 PK deficiency revenue projected at $45M-$50M

Importance:7/10

Sentiment:

0.50

PDUFAregulatoryrevenue guidancesickle cellPK deficiency

Related Companies

$AGIO

Read the original article

Published by Seeking Alpha Healthcare on July 30, 2026 5:54 PM

Read Original